X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (58) 58
oncology (52) 52
index medicus (51) 51
female (50) 50
middle aged (50) 50
adult (42) 42
aged (42) 42
breast cancer (37) 37
immunohistochemistry (33) 33
prognosis (32) 32
chemotherapy (28) 28
cancer (27) 27
male (25) 25
analysis (24) 24
breast neoplasms - drug therapy (20) 20
breast neoplasms - pathology (20) 20
aged, 80 and over (19) 19
research (19) 19
pathology (18) 18
medical research (17) 17
care and treatment (16) 16
disease-free survival (16) 16
expression (16) 16
medicine (16) 16
metastasis (16) 16
receptor, erbb-2 - metabolism (16) 16
clinical trials (15) 15
research article (15) 15
trastuzumab (15) 15
treatment outcome (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
breast neoplasms - metabolism (14) 14
carcinoma (14) 14
genetic aspects (14) 14
hospitals (14) 14
medicine & public health (14) 14
tumors (14) 14
young adult (14) 14
breast neoplasms - genetics (13) 13
multivariate analysis (13) 13
biomarkers, tumor - metabolism (12) 12
her2 (12) 12
in situ hybridization, fluorescence (12) 12
patients (12) 12
protein expression (12) 12
breast neoplasms - mortality (11) 11
gene amplification (11) 11
neoplasm staging (11) 11
oncology, experimental (11) 11
skin and connective tissue diseases (11) 11
anthracyclines (10) 10
antineoplastic agents - therapeutic use (10) 10
cancer therapies (10) 10
diagnosis (10) 10
erbb-2 protein (10) 10
in-situ hybridization (10) 10
mutation (10) 10
proteins (10) 10
survival rate (10) 10
cancer patients (9) 9
cancer research (9) 9
drug therapy (9) 9
gene expression (9) 9
genes (9) 9
health aspects (9) 9
medical prognosis (9) 9
neoplasm metastasis (9) 9
retrospective studies (9) 9
biomarkers, tumor - genetics (8) 8
dense sequential chemotherapy (8) 8
estrogen-receptor (8) 8
medicine, experimental (8) 8
multidisciplinary sciences (8) 8
paclitaxel (8) 8
randomized phase-iii (8) 8
rna, messenger - genetics (8) 8
science (8) 8
survival (8) 8
survival analysis (8) 8
biomarkers, tumor - analysis (7) 7
breast (7) 7
fluorescence (7) 7
fluorescence in situ hybridization (7) 7
follow-up studies (7) 7
gene expression regulation, neoplastic (7) 7
genetics (7) 7
greece (7) 7
laboratories (7) 7
medical colleges (7) 7
metastases (7) 7
neoplasms (7) 7
receptor, erbb-2 - genetics (7) 7
receptors, estrogen - metabolism (7) 7
studies (7) 7
therapy (7) 7
adjuvant chemotherapy (6) 6
amplification (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
biomarkers (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2011, Volume 67, Issue 1, pp. 245 - 245
Journal Article
Journal Article
Journal of Experimental and Clinical Cancer Research, ISSN 1756-9966, 2012, Volume 31, Issue 1, p. 77
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have become a treatment option in non-small-cell lung cancer (NSCLC)... 
Response | Somatic mutation | Erlotinib | Gefitinib | EGFR | Predictive | SURVIVAL | METAANALYSIS | GROWTH-FACTOR-RECEPTOR | ADENOCARCINOMA | EGFR MUTATIONS | CHEMOTHERAPY | K-RAS MUTATIONS | ONCOLOGY | GENE COPY NUMBER | EXPRESSION | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - genetics | Prognosis | Protein-Tyrosine Kinases - metabolism | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Protein-Tyrosine Kinases - genetics | Receptor, Epidermal Growth Factor - metabolism | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - genetics | Survival Rate | Treatment Outcome | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Protein-Tyrosine Kinases - antagonists & inhibitors | Immunohistochemistry | Tyrosine | Medical research | Care and treatment | Analysis | Medicine, Experimental | Medical records | Phenols | Pharmaceutical industry | Lung cancer, Non-small cell | Studies | Pathology | Chemotherapy | Hospitals | Lung cancer | Cell cycle | Biomarkers | Oncology | Mutation | Kinases | Cancer therapies | Patients
Journal Article
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 01/2012, Volume 10, Issue 1, pp. 10 - 10
Background: HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with... 
Mrna expression | Anthracyclines | Gene amplification | Top2a | Randomized study | Cish | Early breast cancer | Taxanes | Her2 | TOP2A | early breast cancer | PREDICTIVE MARKERS | MEDICINE, RESEARCH & EXPERIMENTAL | CISH | TOPOISOMERASE-II-ALPHA | taxanes | IN-SITU HYBRIDIZATION | QUANTITATIVE PCR | ESTROGEN-RECEPTOR | mRNA expression | PARAFFIN-EMBEDDED TISSUE | MESSENGER-RNA | PROTEIN EXPRESSION | CELL-CYCLE | anthracyclines | HER2 | gene amplification | randomized study | Multivariate Analysis | Receptors, Estrogen - metabolism | Antibiotics, Antineoplastic - pharmacology | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Ki-67 Antigen - metabolism | Gene Expression Profiling | RNA, Messenger - metabolism | Receptors, Progesterone - metabolism | DNA-Binding Proteins - metabolism | Dose-Response Relationship, Drug | Paraffin Embedding | Young Adult | Poly-ADP-Ribose Binding Proteins | Breast Neoplasms - enzymology | Antigens, Neoplasm - metabolism | Adult | Female | Chemotherapy, Adjuvant | Gene Expression Regulation, Neoplastic - drug effects | Tissue Fixation | Genes, Neoplasm - genetics | Antigens, Neoplasm - genetics | DNA Topoisomerases, Type II - metabolism | RNA, Messenger - genetics | Risk Factors | Proportional Hazards Models | Treatment Outcome | DNA-Binding Proteins - genetics | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Antibiotics, Antineoplastic - therapeutic use | Breast Neoplasms - pathology | Epirubicin - therapeutic use | DNA Topoisomerases, Type II - genetics | Aged | Epirubicin - pharmacology | Genes | Physiological aspects | Breast cancer | Genetic aspects | Research | Epirubicin | Drug therapy | Health aspects | DNA topoisomerase II | Medical research | Oncology | Cytotoxicity | Cancer therapies | Manuscripts | Medicine | Pathology | Chemotherapy | Hospitals | Writing | Drug dosages | Tumors
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 10/2012, Volume 10, Issue 1, pp. 212 - 212
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, p. e0207707
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2012, Volume 7, Issue 6, p. e37946
Background: The aim of the present study was to investigate the efficacy of adjuvant dose-dense sequential chemotherapy with epirubicin, paclitaxel, and CMF in... 
PHASE-III TRIAL | COOPERATIVE ONCOLOGY GROUP | NEOADJUVANT CHEMOTHERAPY | MULTIDISCIPLINARY SCIENCES | PROTEIN EXPRESSION | TISSUE MICROARRAYS | BRAIN METASTASES | RISK | DENSE SEQUENTIAL CHEMOTHERAPY | PROGNOSTIC VALUE | DOCETAXEL | Immunohistochemistry | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Methotrexate - therapeutic use | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Cyclophosphamide - therapeutic use | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Young Adult | Disease-Free Survival | Fluorouracil - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Epirubicin - therapeutic use | Keratin-5 - metabolism | Adult | Female | Aged | Anthracyclines - therapeutic use | Medical research | Anthracyclines | Estrogen | Adjuvant treatment | Breast cancer | Metastasis | Keratin | Paclitaxel | Medicine, Experimental | Rankings | Progesterone | Health aspects | Cancer | Enrichment | Brain | Cytokeratin | Laboratories | Liver | Estrogens | Clinical trials | Estrogen receptors | Oncology | Nervous system | Paraffin | Cancer therapies | Subgroups | Metastases | Proteins | Cell growth | Mastectomy | Epirubicin | Drug dosages | Risk groups | Epidermal growth factor receptors | Health risks | Patients | Survival | ErbB-2 protein | Medicine | Studies | Pathology | Chemotherapy | Brain research | Hospitals | Anthracycline | Collaboration | Medical prognosis | Biomarkers | Trastuzumab | Tumors
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 01/2011, Volume 67, Issue 1, p. 245
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2018, Volume 142, Issue 1, pp. 66 - 80
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2012, Volume 134, Issue 1, pp. 353 - 362
In spite the close association of the triple-negative breast cancer immunophenotype with hereditary breast cancers and the BRCA1 pathway, there is a lack of... 
Oncology | Hereditary breast–ovarian cancer | BRCA1 | Genetic testing | Medicine & Public Health | Triple-negative breast cancer | Hereditary breast-ovarian cancer | GENOMIC REARRANGEMENTS | FOUNDER MUTATIONS | ESTROGEN-RECEPTOR | PACLITAXEL | EPIRUBICIN | ONCOLOGY | RANDOMIZED PHASE-III | GERMLINE MUTATIONS | DENSE SEQUENTIAL CHEMOTHERAPY | YOUNG-WOMEN | CMF | Carcinoma, Ductal, Breast - genetics | Receptors, Estrogen - metabolism | Carcinoma, Ductal, Breast - epidemiology | Genetic Testing | Prevalence | Hereditary Breast and Ovarian Cancer Syndrome - diagnosis | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Carcinoma, Lobular - epidemiology | Hereditary Breast and Ovarian Cancer Syndrome - metabolism | Patient Selection | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Lobular - genetics | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Carcinoma, Ductal, Breast - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - genetics | Carcinoma, Lobular - diagnosis | Carcinoma, Ductal, Breast - diagnosis | BRCA1 Protein - genetics | Heterozygote | Aged | Carcinoma, Lobular - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - epidemiology | Mutation | BRCA mutations | Oncology, Experimental | Breast cancer | Research | Toy industry | Genetic screening | Prevalence studies (Epidemiology) | Ovarian cancer | Analysis | DNA | Genetic aspects | Diagnosis | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, p. e0180489
Background-Aim To evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various... 
OVEREXPRESSION | COOPERATIVE ONCOLOGY GROUP | PROGNOSTIC-FACTOR | EPIRUBICIN | RANDOMIZED PHASE-III | MULTIDISCIPLINARY SCIENCES | DENSE SEQUENTIAL CHEMOTHERAPY | INHIBITORS | P21 | P27(KIP1) | Immunohistochemistry | Prognosis | Cyclin-Dependent Kinase Inhibitor p27 - analysis | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Young Adult | Cyclin D1 - analysis | Tumor Suppressor Protein p53 - analysis | Cyclin-Dependent Kinase Inhibitor p21 - analysis | Breast - drug effects | Breast Neoplasms - pathology | Triple Negative Breast Neoplasms - diagnosis | Cyclin E - analysis | Survival Analysis | Triple Negative Breast Neoplasms - pathology | Adult | Female | Aged | Breast Neoplasms - diagnosis | Oncogene Proteins - analysis | Breast - pathology | Usage | Analysis | Cell cycle | Clinical trials | Breast cancer | Research | Health sciences | GTP-binding protein | Regulators | Laboratories | Molecular clusters | p53 Protein | Oncology | Paraffin | Cyclin D1 | Kinases | Tissues | Cancer therapies | Formaldehyde | Cell adhesion & migration | Proteins | Medical research | Cyclin-dependent kinases | Clustering | Medicine | Pathology | Cyclin-dependent kinase inhibitor p21 | Hospitals | Medical prognosis | Breast | Tumors | Cancer | Apoptosis
Journal Article